528 material Form 8-K filings that 462 companies we cover made with the SEC in January 2025, each read and summarized by AI: what happened, the key figures, whether it reads positive or negative for shareholders, and how big a deal it is (impact 1-5). All of them were written later, when past filings were added: a selection, not every 8-K of the month (see the note below).
F&G Annuities & Life priced a public offering of $375 million in 7.300% Junior Subordinated Notes due 2065 on January 6, 2025. The company plans to use the net proceeds for general corporate purposes, including repaying or redeeming outstanding indebtedness, and the offering is expected to close on or about January 13, 2025.
Offering size: $375 million aggregate principal amount of 7.300% Junior Subordinated Notes due 2065
Underwriting agreement dated January 6, 2025 with Wells Fargo Securities, BofA Securities, J.P. Morgan, Morgan Stanley and RBC Capital Markets as representatives
Expected closing on or about January 13, 2025, subject to customary closing conditions
Revvity and its subsidiary Revvity Health Sciences entered a new $1.5 billion unsecured revolving credit facility dated January 7, 2025, with Bank of America as administrative agent. The new facility replaces the prior $1.5 billion facility, which was terminated the same day and had been set to run through August 24, 2026; the new one is available through January 7, 2030. As of January 7, 2025, the borrowers had no borrowings and $4.2 million of letters of credit outstanding.
Facility size of $1.5 billion, available through January 7, 2030
Replaces prior $1.5 billion credit agreement dated August 24, 2021, which was terminated January 7, 2025
No borrowings and $4.2 million of letters of credit outstanding as of January 7, 2025
Interest priced at base rate or term SOFR plus a spread tied to Revvity's credit rating
Coherent Corp. entered into Amendment No. 3 to its Credit Agreement on January 2, 2025, replacing $2,232,357,812.50 in existing term B loans with new term loans of the same amount. The new loans carry a lower interest rate margin, reduced from 2.50% to 2.00% for term benchmark loans, with maturities unchanged, which may lower the company's borrowing costs.
Principal amount of term B loans replaced: $2,232,357,812.50, on an equal-amount basis
Term benchmark loan margin cut from 2.50% to 2.00%; base rate loan margin cut from 1.50% to 1.00%
Term benchmark floor set at 0.50%
Maturities of new term B loans, revolving credit facility and term A loan remain unchanged
Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.
Briefs marked “Written later” were written in November 2026 for filings that were by then more than three weeks old, so months before mid-October 2026 hold a selection: every material 8-K of the past year for the 100 largest companies we cover and the last 15 important 8-Ks of every other one. Briefs the number check holds back are not shown or counted. Also: the last 45 days, briefs by company, A–Z and the live SEC filings wire.